Effect of Rosmarinic Acid on Experimental Diabetic Nephropathy

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 4, 2012, Pages 390-395

  Jiang, Wang Lin ^a   Xu, Yong ^a   Zhang, Shu Ping ^a   Hou, Jian ^b   Zhu, Hai Bo ^b  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery Technologies   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; ROSMARINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CELL CULTURE; DIABETIC NEPHROPATHY; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; URINALYSIS; WESTERN BLOTTING;

ANIMALS; BODY WEIGHT; CELLS, CULTURED; CINNAMATES; CONNECTIVE TISSUE GROWTH FACTOR; DEPSIDES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; PILOT PROJECTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

ANIMALIA; RATTUS;

EID: 84858616359     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00828.x     Document Type: Article

References (27)

1. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-99.
2. Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets 2005;6:487-94.
3. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006;40:183-92.
4. Abdel WN, Mason RM. Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 2004;13:53-8.
5. van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant 2005;20:6-10.
6. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004;165:2033-43.
7. Kobayashi T, Okada H, Inoue T, Kanno Y et al. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrol Dial Transplant 2006;21:548-9.
8. Goldschmeding R, Aten J, Ito Y et al. Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 2000;15:296-9.
9. Boor P, Sebeková K, Ostendorf T et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007;22:3391-407.
10. Borkemeyer D, Sorokin A, Dunn MJ. Multiple intracellular MAP kinase signaling cascade. Kidney Int 1996;49:1187-98.
11. Yuan LQ, Lu Y, Luo XH, Xie H, Wu XP, Liao EY. Taurine promotes connective tissue growth factor (CTGF) expression in osteoblasts through the ERK signal pathway. Amino Acids 2007;32:425-30.
12. Nakamura M, Ozaki T, Ishii A, Konishi M, Tsubota Y, Furui T et al. Calcitonin induces connective tissue growth factor through ERK1/2 signaling in renal tubular cells. Exp Mol Med 2009;41:307-15.
13. Gao X, Li J, Huang H, Li X. Connective tissue growth factor stimulates renal cortical myofibroblast-like cell proliferation and matrix protein production. Wound Repair Regen 2008;16:408-15.
14. Jiang WL, Chen XG, Qu GW, Yue XD, Zhu HB, Tian JW et al. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock 2009;32:608-13.
15. Li GS, Jiang WL, Tian JW, Qu GW, Zhu HB, Fu FH. In vitro and in vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine 2010;17:282-8.
16. Karamessinis PM, Tzinia AK, Kitsiou PV, Stetler-Stevenson WG, Michael AF, Fan WW et al. Proximal tubular epithelial cell integrins respond to high glucose by altered cell-matrix interactions and differentially regulate matrixin expression. Lab Invest 2002;82:1081-93.
17. Raij L, Azar S, Keane W, Zhang GZ. Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int 1984;26:137-43.
18. Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003;63:1944-7.
19. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
20. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405.
21. Schück O, Teplan V, Sibová J, Stollová M. Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. Int J Clin Pharmacol Ther 2004;42:93-7.
22. Zerbini G, Bonfanti R, Meschi F, Bognetti E, Paesano PL, Gianolli L et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes 2006;55:2620-5.
23. Paueksakon P, Revelo MP, Ma LJ, Marcantoni C, Fogo AB. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002;61:2142-8.
24. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 2005;10:S11-3.
25. Schmidt-Ott KM. Unraveling the role of connective tissue growth factor in diabetic nephropathy. Kidney Int 2008;73:375-6.
26. Sakai N, Wada T, Furuichi K, Iwata Y, Yoshimoto K, Kitagawa K et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 2005;45:54-65.
27. Sarközi R, Miller B, Pollack V, Feifel E, Mayer G, Sorokin A et al. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells. J Cell Physiol 2007;211:88-100.